DABIGATRAN ETEXILATE MESYLATE | A207961 | HETERO LABS LTD UNIT III
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG et al v. HETERO USA, INC. et al 1 patentANDA 207961dabigatran etexilate mesylate | D.N.J. | 2016-04-26 | Terminated 2016-06-21 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.9198
per ea
Lowest NADAC/Unit
$0.8569
per ea
Brand NDCs
0
Generic NDCs
7
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 31722066632DABIGATRAN ETEXILATE 110 MG CP | $0.9198 | EA | Generic | — | 2026-06-17 |
| 31722066660DABIGATRAN ETEXILATE 110 MG CP | $0.9198 | EA | Generic | — | 2026-06-17 |
| 31722062160DABIGATRAN ETEXILATE 75 MG CAP | $0.8983 | EA | Generic | — | 2026-06-17 |
| 31722062132DABIGATRAN ETEXILATE 75 MG CAP | $0.8983 | EA | Generic | — | 2026-06-17 |
| 31722062232DABIGATRAN ETEXILATE 150 MG CP | $0.8569 | EA | Generic | — | 2026-06-17 |
| 72603023901DABIGATRAN ETEXILATE 150 MG CP | $0.8569 | EA | Generic | — | 2026-06-17 |
| 31722062260DABIGATRAN ETEXILATE 150 MG CP | $0.8569 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.